This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== 25 March === Ukrainian commander-in-chief Valerii Zaluzhnyi posted on Facebook that Ukrainian forces in Bakhmut had managed to "stabilize the situation". President Putin said Russia would go ahead with its plan to station tactical nuclear weapons in Belarus. He also stated that a small number of Iskander missiles able to carry them were already in Belarus. A storage facility for tactical nuclear weapons is to be finished by 1 July.
=== Wound healing === Low level laser therapy has been studied as a potential treatment for chronic wounds, and higher-power lasers have sometimes been successfully used to close acute wounds as an alternative to stitching. However, as of 2012 and due to inconsistent results and the low quality of extant research, reviews in the scientific literature have not supported its widespread application.
Elagolix, sold under the brand name Orilissa, is a gonadotropin-releasing hormone antagonist (GnRH antagonist) medication which is used in the treatment of pain associated with endometriosis in women. It is also under development for the treatment of uterine fibroids and heavy menstrual bleeding in women. The medication was under investigation for the treatment of prostate cancer and enlarged prostate in men as well, but development for these conditions was discontinued. Elagolix is taken by mouth once or twice per day. It can be taken for up to 6 to 24 months, depending on the dosage. Side effects of elagolix include menopausal-like symptoms such as hot flashes, night sweats, insomnia, amenorrhea, mood changes, anxiety, and decreased bone density, among others. Elagolix is a GnRH antagonist, or an antagonist of the gonadotropin-releasing hormone receptor (GnRHR), the biological target of the hypothalamic hormone gonadotropin-releasing hormone (GnRH). By blocking the GnRHR, it dose-dependently suppresses the gonadal production and hence circulating levels of sex hormones such as estradiol, progesterone, and testosterone. Elagolix is a short-acting GnRH antagonist, and can be used to achieve either partial or more substantial suppression of sex hormone levels. Reduced estrogen levels in the endometrium are responsible for the efficacy of elagolix in the treatment of endometriosis. Elagolix was first described in 2008 and was approved for medical use in July 2018.
=== Endocrine === Insulin Resistance, hyperinsulinemia, type II Diabetes, hypertriglyceridemia - Sodium-glucose transport protein 2 inhibitors, metformin, sulfonylureas, DPP-4 inhibitors, short and long-acting insulin
The major benefit of the indirect methodology is that conventional achiral stationary phase/mobile phase system may be used for the separation of the generated diastereomers. Thus, considerable flexibility in chromatographic conditions is available to achieve the desired separation and to eliminate interferences from metabolites and endogenous substances. Moreover, the sensitivity of the method can be enhanced by sensible choice of the CDA and the chromatographic detection system. But this indirect approach to enantiomeric analysis has some potential problems. These include availability of a suitable functional group on the enantiomer for derivatization, enantiomeric purity of the CDA, racemization of the CDA during derivatization, and racemization of the analyte during the derivatization. Currently, however, the application of indirect analytical approaches is in decline.
Sources: en.wikipedia.org
Every building material contains traces of natural radioactive substances, especially 238uranium, 232thorium, and their decay products, and 40potassium. Solidified and effusive rocks such as granite, tuff, and pumice have higher levels of radioactivity. In contrast, sand, gravel, limestone, and natural gypsum (calcium sulfate dihydrate) have low levels of radioactivity. The European Union's Activity Concentration Index (ACI), developed in 1999, can be used to assess radiation exposure from building materials. It replaces the Leningrad summation formula, which was used in 1971 in Leningrad (St. Petersburg) to determine how much radiation exposure from building materials is permissible for humans. The ACI is calculated from the sum of the weighted activities of 40potassium, 226radium, and 232thorium. The weighting takes into account the relative harmfulness to humans. According to official recommendations, building materials with a European ACI value greater than "1" should not be used in large quantities.
==== Nitrogen ==== Nitrogen gas (N2) makes up 78% of the atmosphere and is extremely well mixed over short time-scales, resulting in a homogenous isotopic distribution ideal for use as a reference material. Atmospheric N2 is commonly called AIR when being used as an isotopic reference. In addition to atmospheric N2 there are multiple N isotopic reference materials.
How a policy institute addresses these largely depends on how they work, their ideology vs. evidence credentials, and the context in which they operate including funding opportunities, the degree and type of competition they have and their staff. This functional method addresses the inherit challenge of defining a think tank. As Simon James said in 1998, "Discussion of think tanks...has a tendency to get bogged down in the vexed question of defining what we mean by 'think tank'—an exercise that often degenerates into futile semantics." It is better (as in the Network Functions Approach) to describe what the organisation should do. Then the shape of the organisation should follow to allow this to happen. The following framework (based on Stephen Yeo's description of think tanks' mode of work) is described in Enrique Mendizabal's blog "onthinktanks": First, policy institutes may work in or base their funding on one or more of:
Use of a statistical process control (SPC) software in conjunction with a manual double-seam monitor, computerized double seam scanner, or even a fully automatic double seam inspection system makes the laborious process of double seam inspection faster and much more accurate. Statistically tracking the performance of each head or seaming station of the can seamer allows for better prediction of can seamer issues, and may be used to plan maintenance when convenient, rather than to simply react after bad or unsafe cans have been produced.
Sources: en.wikipedia.org
The king cobra is not considered aggressive. It usually avoids humans and slinks off when disturbed, but is known to aggressively defend incubating eggs and attack intruders rapidly. When alarmed, it raises the front part of its body, extends the hood, shows the fangs and hisses loudly. Wild king cobras encountered in Singapore appeared to be placid, but reared up and struck in self defense when cornered. The king cobra can be easily irritated by closely approaching objects or sudden movements. When raising its body, the king cobra can still move forward to strike with a long distance, and people may misjudge the safe zone. It can deliver multiple bites in a single attack. The hiss of the king cobra is a much lower pitch than many other snakes and many people thus liken its call to a "growl" rather than a hiss. While the hisses of most snakes are of a broad-frequency span ranging from roughly 3,000 to 13,000 Hz with a dominant frequency near 7,500 Hz, king cobra growls consist solely of frequencies below 2,500 Hz, with a dominant frequency near 600 Hz, a much lower-pitched frequency closer to that of a human voice. Comparative anatomical morphometric analysis has led to a discovery of tracheal diverticula that function as low-frequency resonating chambers in king cobra and its prey, the rat snake, both of which can make similar growls.
==== Mouse bioassay ==== The mouse bioassay (MBA) procedure developed by Yasumoto et al. is the official reference method used to analyse for YTX and lipophilic toxins including okadaic acid, dinophysistoxins (DSPs), azaspiracids, and pectenotoxins. The MBA involves injecting the extracted toxin into a mouse and monitoring the mouse survival rate; the toxicity of the sample can be subsequently deduced and the analyte concentration determined. This calculation is made on the basis that one mouse unit (MU) is the minimum quantity of toxin needed to kill a mouse in 24hours. The MU is set by regulating bodies at 0.05 MU/g of animal. The original Yasumoto MBA is subject to interferences from paralytic shellfish toxins and free fatty acids in solution, which cause false positive results. Several modifications to the MBA can be made to allow the test to be performed without these errors. The MBA, however, still has many drawbacks;
== Business career == Paetongtarn is the largest shareholder of SC Asset Corporation and a director of the Thaicom Foundation, a benefactor of her family's wealth. As of 2022, she holds a total of 21 companies valued at approximately ฿68 billion (US$2 billion).
A juice bar is an establishment that primarily serves prepared juice beverages such as freshly squeezed or extracted fruit juices, juice blends, fruit smoothies (a thick fruit drink, often iced), or other juices such as fresh wheatgrass juice. Sometimes other solid ingredients or nutritional supplements may be added as boosters, such as fresh bananas, nuts or nut butter, bodybuilding supplements, soy protein powder, or others such as whey or hemp protein powders, wheat germ, spirulina, or chlorella. Also, if less juice is used with these same ingredients, drinks called health shakes may be produced. Juice bars share some of the characteristics of a coffeehouse, a soda fountain, a café, and a snack bar, such as providing blended drinks and food, such as sandwiches. Juice bars may be standalone businesses in cities or located at gyms, along commuter areas, near lunchtime areas, at beaches, or at tourist attractions. In Mexico, juice bars have become more popular in the 2000s. Mexican juice bars often also sell healthy beverages and snacks.
== Characters == Nathan Byrn. The 17-year-old protagonist. He has straight black hair, olive skin and black eyes. Raised in a family of White witches, he is half White and half Black. He can self-heal extraordinarily fast and transform into animals, much like his father, Marcus. He is the love interest of Annalise O'Brien, and later of Gabriel. Gabriel Boutin. A Black witch stuck in the body of a fain until he is returned to his original witch body. Gabriel is tall and slim, has brown eyes and long, brown hair that falls to his shoulders. He also falls in love with Nathan in Half Bad, and his feelings remain, even though Nathan is with Annalise. There are also two short stories - "Half Lies" and "Half Truth" - from Gabriel's and his sister Michele's points of view about his past and how Gabriel ended up with Nathan. Marcus. Nathan's father is the most feared Black witch of all time. He killed Nathan's siblings' father, among many others. His Gift is transforming into animals but he has also stolen Gifts from many other witches by killing them and eating their hearts. Victoria Van Dal. A Black witch, her gift is making powerful potions. She becomes one of Nathan's most important allies in the rebellion against Soul O'Brien. Nesbitt. Half Black, half Fain, Van's assistant. He is witty, charming, drinks and talks too much. Nathan originally dislikes him but grows fond of him as they live and journey together. Mercury. A powerful Black witch who can control the weather and who holds Annalise prisoner, and will only release her in exchange for Nathan killing his father, Marcus.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.